Form SC TO-C - Written communication relating to an issuer or third party:
SEC Accession No. 0001104659-25-042639
Filing Date
2025-04-30
Accepted
2025-04-30 17:00:57
Documents
9

Document Format Files

Seq Description Document Type Size
1 SC TO-C tm2513674d1_sctoc.htm SC TO-C 25070
2 EXHIBIT 99.1 tm2513674d1_ex99-1.htm EX-99.1 22371
3 EXHIBIT 99.2 tm2513674d1_ex99-2.htm EX-99.2 10461
4 EXHIBIT 99.3 tm2513674d1_ex99-3.htm EX-99.3 13363
5 GRAPHIC tm2513674d1_ex99-1img001.jpg GRAPHIC 3968
6 GRAPHIC tm2513674d1_ex99-1img002.jpg GRAPHIC 5275
7 GRAPHIC tm2513674d1_ex99-3img001.jpg GRAPHIC 20746
8 GRAPHIC tm2513674d1_ex99-2img001.jpg GRAPHIC 134108
9 GRAPHIC tm2513674d1_ex99-2img002.jpg GRAPHIC 41277
  Complete submission text file 0001104659-25-042639.txt   356655
Mailing Address LICHTSTRASSE 35 BASEL V8 CH 4056
Business Address LICHTSTRASSE 35 BASEL V8 CH 4056 01141613241111
NOVARTIS AG (Filed by) CIK: 0001114448 (see all company filings)

EIN.: 000000000 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: SC TO-C
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Subject) CIK: 0001505512 (see all company filings)

EIN.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC TO-C | Act: 34 | File No.: 005-87002 | Film No.: 25896632
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)